구조모아 (StructureMoa)항암 chemical structure spider web
방문National Cancer Institute (NCI)
Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells(National Cancer Institute (NCI))은 BCMA 표적 세포·유전자 치료로, Myeloma-Multiple; Myeloma, Plasma-Cell 영역에서 개발·상용화 중입니다. 작용기전: targets for bsAbs on multiple myeloma cells are B cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor. Phase 1 안전성·PK 탐색 단계입니다. PFS: 36.6. 차별점: novel therapeutics.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
BCMA
Myeloma-Multiple; Myeloma, Plasma-Cell
Active
2026-09-02
Data Confidence · Medium
Development Signal · Watch
bispecific antibodies in relapsed or refractory multiple myeloma
lentiviral constructs, and durable clearance of myeloma cells after multiple rechallenges
humanized bispecific antibody approved for patients with relapsed/refractory multiple myeloma (RRMM)
novel therapeutics
targets for bsAbs on multiple myeloma cells are B cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor
cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, as well as significant infecti
apoptosis through microtubule inhibition, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagoc
BCMA) is a high
Resistance to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Biology, Clinical Patterns, and Strategies to Overcome Treatment
구조화 데이터
xenograft model
mouse
PK
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
National Cancer Institute (NCI)
Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells(National Cancer Institute (NCI))은 BCMA 표적 세포·유전자 치료로, Myeloma-Multiple; Myeloma, Plasma-Cell 영역에서 개발·상용화 중입니다. 작용기전: targets for bsAbs on multiple myeloma cells are B cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor. Phase 1 안전성·PK 탐색 단계입니다. PFS: 36.6. 차별점: novel therapeutics.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
BCMA
Myeloma-Multiple; Myeloma, Plasma-Cell
Active
2026-09-02
Data Confidence · Medium
Development Signal · Watch
bispecific antibodies in relapsed or refractory multiple myeloma
lentiviral constructs, and durable clearance of myeloma cells after multiple rechallenges
humanized bispecific antibody approved for patients with relapsed/refractory multiple myeloma (RRMM)
novel therapeutics
targets for bsAbs on multiple myeloma cells are B cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor
cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, as well as significant infecti
apoptosis through microtubule inhibition, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagoc
BCMA) is a high
Resistance to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Biology, Clinical Patterns, and Strategies to Overcome Treatment
구조화 데이터
xenograft model
mouse
PK
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.